Company intelligence / Profile preview

Glycoform

Abingdon, Oxfordshire, United Kingdom

Ownership: Private
Development stage: Other

Overview

Glycoform was a biotechnology company spun out from the University of Oxford that specialized in site-specific protein glycosylation technology. The company's platform enabled the production of homogeneous glycoforms of therapeutic proteins, aiming to improve their pharmacological properties such as half-life and immunogenicity. Their lead research programs included glycosylated versions of Interferon alpha-2b for Hepatitis C and Erythropoietin for anemia. In 2013, Glycoform was acquired by ScinoPharm Taiwan for approximately $5.8 million to integrate its technology into ScinoPharm's biologics development pipeline.

Therapeutic areas: HematologyInfectious Diseases
Modalities: Recombinant protein
Industry: Biotech

Beyond the preview

Go deeper on Glycoform.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glycoform.

Explore the full profile